Department of Neuroscience, Graduate School of Pharmaceutical Sciences, Hokkaido University, Sapporo, Japan.
Ann Neurol. 2011 Jun;69(6):1026-31. doi: 10.1002/ana.22343.
The most common pathogenesis for familial Alzheimer's disease (FAD) involves misprocessing (or alternative processing) of the amyloid precursor protein (APP) by γ-secretase due to mutations of the presenilin 1 (PS1) gene. This misprocessing/alternative processing leads to an increase in the ratio of the level of a minor γ-secretase reaction product (Aβ42) to that of the major reaction product (Aβ40). Although no PS1 mutations are present, altered Aβ42/40 ratios are also observed in sporadic Alzheimer's disease (SAD), and these altered ratios apparently reflect deposition of Aβ42 as amyloid.
Using immunoprecipitation-mass spectrometry with quantitative accuracy, we analyzed in the cerebrospinal fluid (CSF) of various clinical populations the peptide products generated by processing of not only APP but also an unrelated protein, alcadein (Alc). Alc undergoes metabolism by the identical APP α-secretases and γ-secretases, yielding a fragment that we have named p3-Alc(α) because of the parallel genesis of p3-Alc(α) peptides and the p3 fragment of APP. As with Aβ, both major and minor p3-Alc(α) s are generated. We studied the alternative processing of p3-Alc(α) in various clinical populations.
We previously reported that changes in the Aβ42/40 ratio showed covariance in a linear relationship with the levels of p3-Alc(α) [minor/major] ratio in media conditioned by cells expressing FAD-linked PS1 mutants. Here we studied the speciation of p3-Alc(α) in the CSF from 3 groups of human subjects (n = 158): elderly nondemented control subjects; mild cognitive impairment (MCI) subjects with a clinical dementia rating (CDR) of 0.5; SAD subjects with CDR of 1.0; and other neurological disease (OND) control subjects. The CSF minor p3-Alc(α) variant, p3-Alc(α) 38, was elevated (p < 0.05) in MCI subjects or SAD subjects, depending upon whether the data were pooled and analyzed as a single cohort or analyzed individually as 3 separate cohorts.
These results suggest that some SAD may involve alternative processing of multiple γ-secretase substrates, raising the possibility that the molecular pathogenesis of SAD might involve γ-secretase dysfunction.
家族性阿尔茨海默病(FAD)最常见的发病机制是由于早老素 1(PS1)基因突变导致γ-分泌酶对淀粉样前体蛋白(APP)的异常加工(或替代加工)。这种异常加工/替代加工导致次要 γ-分泌酶反应产物(Aβ42)的水平与主要反应产物(Aβ40)的比值增加。尽管没有 PS1 突变,但散发性阿尔茨海默病(SAD)中也观察到 Aβ42/40 比值改变,这些比值改变显然反映了 Aβ42 的沉积为淀粉样蛋白。
使用免疫沉淀-质谱法,我们分析了不同临床人群的脑脊液(CSF)中,不仅是 APP,还有一种不相关的蛋白 alcadein(Alc)的加工产物。Alc 通过相同的 APP α-分泌酶和 γ-分泌酶代谢,生成我们命名为 p3-Alc(α)的片段,因为 p3-Alc(α)肽和 APP 的 p3 片段是平行生成的。与 Aβ一样,都会生成主要和次要的 p3-Alc(α)片段。我们研究了 p3-Alc(α)在不同临床人群中的替代加工。
我们之前报道过,Aβ42/40 比值的变化与表达 FAD 相关 PS1 突变体的细胞条件培养基中 p3-Alc(α)[次要/主要]比值的变化呈线性相关。在这里,我们研究了来自 3 组人类受试者(n=158)的 CSF 中 p3-Alc(α)的分类:老年非痴呆对照组;认知障碍(MCI)组,临床痴呆评定量表(CDR)为 0.5;SAD 组,CDR 为 1.0;以及其他神经疾病(OND)对照组。CSF 中的小 p3-Alc(α)变体 p3-Alc(α)38 在 MCI 组或 SAD 组中升高(p<0.05),这取决于数据是作为一个单一队列汇总和分析,还是作为 3 个独立队列分别分析。
这些结果表明,一些 SAD 可能涉及多个 γ-分泌酶底物的替代加工,这增加了 SAD 的分子发病机制可能涉及 γ-分泌酶功能障碍的可能性。